Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.52 |
| ▸ | NAMPT | P43490 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PRKX | P51817 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5615835 | 0.90 | MMP13 (0.53) | MMP13ROCK2NAMPTPRKACAPRKX | |
| SCHEMBL5616130 | 0.87 | ROCK2 (0.52) | MMP13HIF1AROCK2NAMPTKDM4E | |
| SCHEMBL14602334 | 0.85 | MMP13 (0.56) | MMP13HIF1AROCK2NAMPTLMNA | |
| SCHEMBL5615860 | 0.85 | ROCK2 (0.53) | MMP13HIF1AROCK2NAMPTKDM4E | |
| SCHEMBL14602329 | 0.85 | NAMPT (0.56) | MMP13NPC1RAB9AHIF1AROCK2 | |
| SCHEMBL14602327 | 0.84 | NAMPT (0.53) | MMP13HIF1AROCK2NAMPTKDM4E | |
| SCHEMBL14602331 | 0.83 | ROCK2 (0.52) | MMP13NPC1RAB9AHIF1AROCK2 | |
| SCHEMBL5615596 | 0.83 | ALDH1A1 (0.50) | MMP13HIF1AROCK2NAMPTCYP3A4 | |
| SCHEMBL4720766 | 0.83 | MMP13 (0.73) | MMP13RAB9AROCK2LMNACYP3A4 | |
| SCHEMBL8358822 | 0.83 | MMP13 (0.69) | MMP13RAB9AROCK2LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | claimed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | claimed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | MMP13, DPYD, MMP1 | MMP13 1/4885NPC1 4376/4885RAB9A 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.